Fractional CO2 Laser Therapy for Survivors of Breast Malignancies

PRIMARY OBJECTIVES:

I. To demonstrate the feasibility of fractionated CO2 laser treatments in patients with
breast cancer with vaginal atrophy by determining treatment completion rates and tolerability
of treatment.

II. To demonstrate the efficacy of fractionated CO2 laser treatments in patients with breast
cancer with vaginal atrophy as determined by improvement from baseline to post treatment in
the score of the Vaginal Assessment Scale (VAS).

SECONDARY OBJECTIVES:

I. Sexual behavior/function as measured by the Sexual Experiences Scare, Global sexual
satisfaction scale, Female Sexual Function Index (FSFI), and the Female Sexual Distress Scare
(FSDS).

II. Other symptoms of urogenital atrophy using the Urogenital Distress Inventory (UDI).

III. Overall patient assessment of symptoms by Patient Global Impression of Improvement scale
(PGI-I).

OUTLINE:

Patients undergo fractional CO2 laser therapy every 4-6 weeks for 3 treatments.

After completion of study treatment, patients are followed up at 4 weeks.

Inclusion Criteria:

- Women with non-metastatic breast cancer with any hormone receptor and Her 2 neu status
who have completed surgery, chemotherapy, and radiation and are currently on endocrine
therapy, single agent Herceptin, or observation

- Symptoms of urogenital atrophy including dyspareunia or vaginal dryness

Exclusion Criteria:

- Patients with metastatic breast cancer

- Vaginal stenosis which would not allow vaginal probe to be placed (based on physician
exam)

- Active genital infection at the time of enrollment (if present initially, can be
treated and then patient can be re-evaluated for eligibility)

- Pelvic organ prolapse greater than stage II

- Prior reconstructive pelvic surgery involving mesh

- Hormone replacement therapy, vaginal estrogen therapy, DHEA, or biosynthetics within 6
weeks prior to enrollment